As a part of the National Institute of Standards and Technology (NIST) Genome Editing Consortium, BioSkryb will help enable increased confidence in gene edited research and commercial products
DURHAM, N.C. – September 13, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by e…
Strategic distribution agreement with Research Instruments expands access to BioSkryb’s best-in-class single-cell multiomics portfolio throughout Southeast Asia
DURHAM, N.C. – August 30, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic…
U.S. issued patent expands BioSkryb’s IP portfolio to four granted patents in key geographic markets worldwide
DURHAM, N.C. – August 17, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to…
The product solution combines HP’s new D100 Single Cell Dispenser with BioSkryb’s ResolveDNA® technology to enable the investigation of large single-cell genomics studies with unprecedented coverage and accuracy
DURHAM, N.C. – August 3, 2023 - BioSkryb Genomics, a pioneer in comprehensive single…
LEIDEN July 18, 2023 - BIOKÉ, a leading distributor of life science technologies throughout Europe, has partnered with BioSkryb Genomics (BioSkryb), a pioneer in comprehensive single-cell multiomic research solutions, to distribute Primary Template-directed Amplification (PTA) technology acr…
BioSkryb will present new findings at AACR 2023 that challenge the status quo in the single-cell analysis market
DURHAM, N.C. – April 12, 2023 - BioSkryb Genomics, a pioneer in comprehensive single-cell multiomic research solutions, today announced that it will share new, groundbreaking research rel…
Comprehensive system that enables unmatched single cell multiomic analysis is now widely available following the completion of a successful Early Access Program
DURHAM, N.C. – February 7, 2023 - BioSkryb Genomics, a pioneer in comprehensive single cell multiomic research solutions, today announced t…
Suresh Pisharody brings strong leadership experience honed at Illumina, Thermo Fisher Scientific, and Guardant Health to lead BioSkryb in its next phase of growth
DURHAM, N.C. – January 31, 2023 - BioSkryb Genomics, a pioneer in comprehensive single-cell multi-omic research solutions, has appointed …
New partnership brings transformative, high-resolution single-cell genomic technology to the field of preimplantation genetic testing in the pursuit of improved discovery and clinical outcomes.
DURHAM, N.C., October 18, 2022 – BioSkryb Genomics, a pioneer in developing scientifically advanced single…
This new partnership brings high-resolution, single-cell whole genome and whole transcriptome analysis to Europe. This partnership will enable novel insights and deep cellular characterization required in the evaluation, creation, and validation of new generation biologics and therapeutics in target…
